ADAR and B-cell chronic lymphocytic leukemia: Our data on MEC1 cells further suggest that interference with ADAR function renders CLL cells more susceptible to distinct therapeutic regimens in vitro, which makes ADAR an interesting target for future combination-treatment strategies.